Clinical Trials
91
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (65 trials with phase data)• Click on a phase to view related trials
Rezafungin for Treatment of Chronic Pulmonary Aspergillosis (CPA) in Adults With Limited Treatment Options
- First Posted Date
- 2025-01-27
- Last Posted Date
- 2025-08-29
- Lead Sponsor
- Mundipharma Research Limited
- Target Recruit Count
- 60
- Registration Number
- NCT06794554
- Locations
- 🇦🇹
Kepler University Hospital, Linz, Austria
🇧🇪Brussels University Hospital, Brussels, Belgium
🇧🇪UZ Gent, Ghent, Belgium
Rezafungin for Treatment of Pneumocystis Pneumonia in HIV Adults
- Conditions
- Pneumocystis Pneumonia
- Interventions
- Drug: Co-Trimoxazole
- First Posted Date
- 2023-04-28
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Mundipharma Research Limited
- Target Recruit Count
- 50
- Registration Number
- NCT05835479
- Locations
- 🇿🇦
University of Cape Town, Cape Town, South Africa
🇿🇦Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa
🇿🇦Helen Joseph Hospital, Johannesburg, South Africa
Rezafungin Paediatric PK Study in Paediatric Subjects From Birth to <18 Years of Age
- First Posted Date
- 2022-09-09
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- Mundipharma Research Limited
- Target Recruit Count
- 32
- Registration Number
- NCT05534529
- Locations
- 🇩🇪
Universitätsklinikum Essen Zentrum für Kinder- und Jugendmedizin, Essen, Germany
🇩🇪Universitätsklinikum Frankfurt, Goethe Universität Klinik für Kinder- und Jugendmedizin, Frankfurt, Germany
🇩🇪Universitätsklinikum Münster Klinik für Kinder- und Jugendmedizin, Münster, Germany
Study of Tinostamustine for Adjuvant Treatment of Glioblastoma
- Conditions
- Glioblastoma Multiforme
- Interventions
- First Posted Date
- 2022-06-27
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Mundipharma Research Limited
- Target Recruit Count
- 12
- Registration Number
- NCT05432375
- Locations
- 🇪🇸
Hospital Universitario Vall d'Hebron, Barcelona, Spain, Barcelona, Spain
🇪🇸Hospital Universitario Ramón y Cajal, Madrid, Spain, Madrid, Spain
🇪🇸South Texas Accelerated Research Therapeutics (START), Madrid, Spain
Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation
- Conditions
- PneumocystisInvasive Fungal DiseaseProphylaxis of Invasive Fungal InfectionsMycosesFungal InfectionFungemiaMold InfectionAspergillusCandidemiaInvasive Candidiasis
- Interventions
- Drug: Intravenous PlaceboDrug: Trimethoprim-sulfamethoxazole (TMP/SMX)Drug: Oral Placebo
- First Posted Date
- 2020-04-30
- Last Posted Date
- 2025-07-29
- Lead Sponsor
- Mundipharma Research Limited
- Target Recruit Count
- 600
- Registration Number
- NCT04368559
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
🇺🇸University of Minnesota Physicians, Minneapolis, Minnesota, United States
🇺🇸Mary Hitchcock Memorial Hospital Dartmouth-Hitchcock, Lebanon, New Hampshire, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 8
- Next